Krishna Institute of Medical SciencesQ1 FY25

Krishna Institute of Medical Sciences Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹768.3P/E: 158.8Market Cap: ₹32.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Expansion plans include adding 350-400 beds via new towers and new hospitals in Thane, Nashik, Bengaluru, and Vizag.
  • Vizag hospital acquisition currently generates around INR 65-70 crores revenue, with potential to scale back to INR 120-150 crores.
  • IP volumes show consistent growth (7.5% YoY), with ongoing efforts to optimize Operational Metrics like Average Length of Stay (ALOS).
  • Existing hospitals expected to sustain growth, with incremental contributions from newly acquired or commissioned hospitals like Queen’s NRI and Nashik.
  • Occupancy targets of 65-70% over next 3-4 years expected to drive volume growth.
  • Insurance penetration growth is significant in metro and Tier 1 cities but slower in Tier 2 and 3.
  • EBITDA margin growth expected with revenue scale-up and new specialties added.
  • Capital constraints may limit bed capacity expansion unless leverage or funding (IPO/debt) raised.

See what Krishna Institute of Medical Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • KIMS Hospitals plans to fund growth primarily through internal accruals and debt while maintaining a debt-equity ratio within 0.75:1 and debt-to-EBITDA below 1.75:1.
  • The company may slightly exceed their capex and EBITDA limits in the next 2-3 quarters but plans to stabilize thereafter.
  • For expansion opportunities, they consider two options: raising funds via an IPO or taking on some debt leverage.
  • Current average cost of borrowing is about 8.5%, and they expect this to continue in the near term.
  • No immediate plans for a large-scale equity raise; focus is on using internal resources complemented by manageable debt to fund ongoing and future expansions.
  • Debt is expected to increase from around INR1,150 crores as of June 2024 to INR1,600-1,700 crores by year-end due to new hospital commissions.

See what Krishna Institute of Medical Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Construction of a new tower replacing demolished Block 1 and Block 2 at Secunderabad, accommodating 350-400 incremental beds; capex incurred over time as required (Page 18).
  • Vizag unit acquisition with potential for scale-up; capital costs to be managed via internal accruals and controlled debt (Page 20, 7).
  • Capex planned for upgrading acquired cancer facility (~INR 20-25 crores for renovations) without major medical equipment spend for 2-3 years (Page 8).
  • New hospital cluster development in Karnataka (Sarjapura land parcel) planned post stabilization of currently acquired hospitals; equity infusion from partners (Page 12).
  • Upcoming hospital launches in Nashik, Thane, and Bengaluru on track; Nashik operationalizing 75-80 beds, capex partially incurred or ongoing (Page 6, 7, 16).
  • Capex and EBITDA cautiously managed; possibility to cross existing limits temporarily in 2-3 quarters to seize growth opportunities, with options for IPO or limited debt leverage if needed (Page 20).
  • Capital constraint is a primary limit; company aims to keep debt-equity at 0.75:1 and debt-to-EBITDA at 1.75:1 (Page 16).

Track Krishna Institute of Medical Sciences — get its next earnings analysis in your feed

How does Krishna Institute of Medical Sciences rank vs peers in Healthcare Services?

Pro feature
ThisKrishna Institute of Medical Sciences
Rev 3Mar 3

How does Krishna Institute of Medical Sciences rank in Healthcare Services?

Compare Krishna Institute of Medical Sciences against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →